New data from a large, international clinical trial find that patients with newly-diagnosed chronic myeloid leukemia who received Novartis' Glivec (imatinib) at 800mg/day as their initial treatment achieved clinical milestones significantly faster than those on the standard 400mg/day dose.
The TOPS trial is the first Phase III, randomized, controlled study designed to evaluate the potential benefits of an 800mg starting dose across all risk categories of newly-diagnosed, previously-untreated patients with Philadelphia chromosome-positive chronic myeloid leukemia, noted the Swiss drug major.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze